Beijing SL Pharmaceutical Co Ltd (002038) — Cash Flow-to-Debt Ratio
Beijing SL Pharmaceutical Co Ltd (002038) has a Cash Flow-to-Debt Ratio of 0.20x as of September 2025, meaning its operating cash flow of CN¥66.55 Million could theoretically repay 0% of its total liabilities (CN¥327.96 Million) in one year. See Beijing SL Pharmaceutical Co Ltd (002038) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beijing SL Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2003–2025)
Historical debt coverage capacity for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Beijing SL Pharmaceutical Co Ltd.
Annual Cash Flow-to-Debt Ratio for Beijing SL Pharmaceutical Co Ltd (2003–2025)
Year-by-year debt coverage analysis for Beijing SL Pharmaceutical Co Ltd. Check 002038 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.29x | CN¥257.66 Million | CN¥883.49 Million | ▼ -48.5% |
| 2024 | 0.57x | CN¥225.49 Million | CN¥398.37 Million | ▼ -42.5% |
| 2023 | 0.98x | CN¥460.20 Million | CN¥467.72 Million | ▲ +0.1% |
| 2022 | 0.98x | CN¥389.82 Million | CN¥396.60 Million | ▼ -8.1% |
| 2021 | 1.07x | CN¥464.63 Million | CN¥434.23 Million | ▲ +5.5% |
| 2020 | 1.01x | CN¥415.84 Million | CN¥410.09 Million | ▼ -38.5% |
| 2019 | 1.65x | CN¥665.83 Million | CN¥403.76 Million | ▲ +59.7% |
| 2018 | 1.03x | CN¥485.17 Million | CN¥469.73 Million | ▼ -22.5% |
| 2017 | 1.33x | CN¥380.72 Million | CN¥285.67 Million | ▼ -49.2% |
| 2016 | 2.62x | CN¥396.86 Million | CN¥151.19 Million | ▼ -22.8% |
| 2015 | 3.40x | CN¥504.87 Million | CN¥148.40 Million | ▲ +0.9% |
| 2014 | 3.37x | CN¥465.00 Million | CN¥137.92 Million | ▲ +19.5% |
| 2013 | 2.82x | CN¥347.41 Million | CN¥123.09 Million | ▼ -25.5% |
| 2012 | 3.79x | CN¥398.60 Million | CN¥105.17 Million | ▼ -16.2% |
| 2011 | 4.53x | CN¥228.59 Million | CN¥50.52 Million | ▼ -29.3% |
| 2010 | 6.40x | CN¥238.13 Million | CN¥37.22 Million | ▲ +34.8% |
| 2009 | 4.75x | CN¥174.41 Million | CN¥36.75 Million | ▼ -36.7% |
| 2008 | 7.50x | CN¥194.32 Million | CN¥25.91 Million | ▲ +194.6% |
| 2007 | 2.55x | CN¥88.36 Million | CN¥34.71 Million | ▲ +56.6% |
| 2006 | 1.63x | CN¥57.55 Million | CN¥35.41 Million | ▼ -19.8% |
| 2005 | 2.03x | CN¥47.48 Million | CN¥23.42 Million | ▲ +84.0% |
| 2004 | 1.10x | CN¥31.26 Million | CN¥28.38 Million | ▲ +32.6% |
| 2003 | 0.83x | CN¥30.55 Million | CN¥36.78 Million | — |